Medtronic (NYSE:MDT) EVP Michael Marinaro Sells 10,420 Shares of Company Stock

by · The Markets Daily

Medtronic PLC (NYSE:MDT – Get Free Report) EVP Michael Marinaro sold 10,420 shares of the company’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $96.00, for a total value of $1,000,320.00. Following the transaction, the executive vice president directly owned 105,916 shares in the company, valued at $10,167,936. This represents a 8.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Medtronic Stock Down 0.7%

NYSE MDT traded down $0.66 during trading on Friday, hitting $94.79. The company’s stock had a trading volume of 30,274,266 shares, compared to its average volume of 11,408,682. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54. The company has a market cap of $121.25 billion, a PE ratio of 23.35, a P/E/G ratio of 2.15 and a beta of 0.55. The business’s 50 day simple moving average is $90.87 and its 200-day simple moving average is $84.95. Medtronic PLC has a fifty-two week low of $73.31 and a fifty-two week high of $106.33.

Medtronic (NYSE:MDT – Get Free Report) last issued its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, topping analysts’ consensus estimates of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The business had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. During the same quarter in the previous year, the firm earned $1.26 earnings per share. The company’s revenue was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, equities analysts anticipate that Medtronic PLC will post 5.98 EPS for the current fiscal year.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend is Friday, September 25th. Medtronic’s payout ratio is currently 70.94%.

Institutional Investors Weigh In On Medtronic

Several hedge funds have recently added to or reduced their stakes in the business. Arlington Trust Co LLC increased its stake in Medtronic by 11.6% in the second quarter. Arlington Trust Co LLC now owns 1,157 shares of the medical technology company’s stock valued at $91,000 after purchasing an additional 120 shares in the last quarter. Bigelow Investment Advisors LLC raised its holdings in Medtronic by 1.1% in the first quarter. Bigelow Investment Advisors LLC now owns 11,125 shares of the medical technology company’s stock worth $964,000 after purchasing an additional 121 shares during the period. Bank & Trust Co boosted its position in shares of Medtronic by 2.8% during the second quarter. Bank & Trust Co now owns 4,373 shares of the medical technology company’s stock worth $342,000 after purchasing an additional 121 shares in the last quarter. Grove Bank & Trust boosted its position in shares of Medtronic by 1.2% during the third quarter. Grove Bank & Trust now owns 10,564 shares of the medical technology company’s stock worth $912,000 after purchasing an additional 124 shares in the last quarter. Finally, Integrity Alliance LLC. grew its holdings in shares of Medtronic by 1.7% in the 2nd quarter. Integrity Alliance LLC. now owns 7,388 shares of the medical technology company’s stock valued at $578,000 after buying an additional 125 shares during the period. 82.06% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on MDT. UBS Group reiterated a “cautious” rating on shares of Medtronic in a research note on Wednesday. Weiss Ratings upgraded Medtronic from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, September 4th. Robert W. Baird raised their price objective on Medtronic from $91.00 to $100.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 2nd. Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a report on Wednesday. Finally, BTIG Research dropped their target price on Medtronic from $100.00 to $99.00 and set a “buy” rating on the stock in a research report on Monday. Seventeen equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $102.88.

View Our Latest Stock Analysis on Medtronic

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

  • Positive Sentiment: Medtronic’s Stealth AXiS surgical system and Corsano multi-parameter wearable were named to TIME’s 2026 Best Inventions list. The recognition supports the company’s innovation strategy and could improve visibility for its surgical and monitoring businesses. Medtronic Named to TIME Best Inventions of 2026
  • Positive Sentiment: Medtronic continues expanding in cardiac ablation, robotics, hypertension and digital surgery. Recent sales and profit growth, along with a raised fiscal outlook, provide support for the longer-term investment case. Is Medtronic Stock a Buy Now That Sales Growth Has Picked Up?
  • Neutral Sentiment: Medtronic completed the separation of MiniMed, exchanging its remaining shares and leaving the diabetes-technology company fully independent. The transaction simplifies MDT’s portfolio and may allow greater focus on higher-growth medical-device businesses, but it also removes direct ownership of MiniMed and changes the company’s revenue mix. Medtronic Completes Separation of MiniMed Group
  • Negative Sentiment: Analyst sentiment remains cautious: Piper Sandler assigned a Hold rating, while Barclays began coverage at Equal Weight. These ratings suggest limited near-term upside after MDT’s recent advance. Medtronic Receives a Hold from Piper Sandler
  • Negative Sentiment: Tariffs, inflation and unfavorable currency movements could pressure Medtronic’s margins. ETFs also reportedly sold $222.5 million of MDT shares on October 13, adding a potential short-term technical headwind. Is it Apt to Retain Medtronic Stock in Your Portfolio Now?

About Medtronic

(Get Free Report)

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.

Featured Articles